Combining anti-PD-1 antibodies with Mn2+-drug coordinated multifunctional nanoparticles for enhanced cancer therapy

Cell membrane coated-nanoparticles for cancer immunotherapy

“…This part is summarized in Table 3 62 , 79 , 89 , 91 , 95 , 107 , 117 , 118 , 119 , 121 , 122 , 124 , 125 , 126 , 129 , 134 , 137 , 139 , 140 , 147 , 148 , 149 , 150 , 151 , 152 , 153 , 154 , 155 , 156 , 157 , 158 , 159 , 160 , 161 , 162 , 163 , 164 . Due to discrepancies in proteins or molecules on different cell membranes, the functions of these membrane-derived cell membrane-coated nanoparticles are also different.…”

Red‐Blood‐Cell‐Membrane‐Coated Metal‐Drug Nanoparticles for Enhanced Chemotherapy

“…In recent years, a new approach of directly coordinating metal ions with therapeutic agents to prepare drug delivery systems has attracted interest. [50,51] We herein report a new type of metal-drug nanoparticles (MDNs) via self-assembling of Fe 3 + ions and anticancer drugs DOX as bridging ligands, as shown in Figure 1a. This system shows high drug-loading ability owing to the fact that anticancer drugs directly acted as the bridging ligands.…”

Targeting the PD-1/PD-L1 axis for cancer treatment: a review on nanotechnology

“…Red blood cell membranes were used to coat on the surface of nanosystems which improve the dispersity and stability of NPs, whereas the loading of doxorubicin and the photosensitizer chlorin e6 served the purposes of chemotherapy and phototherapy, respectively. Strikingly, this combination of chemotherapy and photodynamic therapy not only induced a significant decrease in the primary tumours, but also restricted the growth of distant tumours [ 22 ].…”

“…This self-assembled nanosystem blocked PD-L1 and demonstrated improved anti-tumour efficacy in combination with photodynamic immunotherapy [ 55 ]. This strategy employed a couple of combinations such as anti-PD-1 and Ce6 [ 22 ], BMS-202 a small-molecule inhibitor of the PD-1/PD-L1 and Ce6 [ 62 ], the photosensitizer BDP-I-N and anti-PD-L1 [ 63 ], the photosensitizer mTHPC, and anti-PD-L1 [ 64 ] in nanocarriers.…”